Neutralization of Staphylococcus aureus Protein A Prevents Exacerbated Osteoclast Activity and Bone Loss during Osteomyelitis
Ana-Katharina E. Gehrke, Andrea Mendoza-Bertelli, Camila Ledo, Cintia D. González, Mariángeles Noto Llana, Cintia Blanco, Daniel O. Sordelli, Nicole E. Putman, James E. Cassat, M. Victoria Delpino, Marisa I. Gómez
Abstract
, leading to reduced expression levels of cathepsin K, reduced expression of markers associated with abnormal bone formation, and decreased trabecular bone loss during osteomyelitis. Taken together, these results demonstrate the feasibility of using anti-SpA antibodies as an antivirulence adjunctive therapy that may prevent the development of pathological conditions that not only damage the bone but also favor bacterial escape from antimicrobials and the immune system.
Topics & Concepts
Staphylococcus aureusOsteomyelitisOsteoclastAntimicrobialMicrobiologyStaphylococcal infectionsImmune systemStaphylococcusMedicineBone InfectionImmunologyMicrococcaceaeBiologyBacteriaInternal medicineGeneticsReceptorOrthopedic Infections and TreatmentsAntimicrobial Resistance in StaphylococcusInfective Endocarditis Diagnosis and Management